Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)  - Pipeline Review, H2 2016', provides in depth analysis on Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)  targeted pipeline therapeutics. 

The report provides comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)  targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) 
- The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)  targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)  targeted therapeutics and enlists all their major and minor projects 
- The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)  targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)  targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)  development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Overview 7
Therapeutics Development 8
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Products under Development by Stage of Development 8
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Products under Development by Therapy Area 9
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Products under Development by Indication 10
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Products under Development by Companies 13
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Products under Development by Universities/Institutes 15
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development 22
Addex Therapeutics Ltd 22
Denovo Biopharma, LLC 23
Domain Therapeutics SA 24
Eli Lilly and Company 25
Johnson & Johnson 26
Merck & Co., Inc. 27
Taisho Pharmaceutical Holdings Co., Ltd. 28
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles 29
ADX-92639 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
JNJ-40411813 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LSN-2535717 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
LY-2607540 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
LY-341495 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
MGS-0028 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
pomaglumetad methionil - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Antagonize mGluR2 for Parkinson's Disease - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Projects 43
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products 46
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Featured News & Press Releases 47
Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy 47
Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death 47
Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms 48
Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 48
Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 49
Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 51
Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 52
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 52
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 53
Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms 54
Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia 54
Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 55
Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program 56
Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator 56
Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Addex Therapeutics Ltd, H2 2016 22
Pipeline by Denovo Biopharma, LLC, H2 2016 23
Pipeline by Domain Therapeutics SA, H2 2016 24
Pipeline by Eli Lilly and Company, H2 2016 25
Pipeline by Johnson & Johnson, H2 2016 26
Pipeline by Merck & Co., Inc., H2 2016 27
Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 28
Dormant Projects, H2 2016 43
Dormant Projects (Contd..1), H2 2016 44
Dormant Projects (Contd..2), H2 2016 45
Discontinued Products, H2 2016 46